NRx CEO resigns; Chairman Javitt takes interim CEO; shareholders approve reverse split

NRX Pharmaceuticals, Inc.

CEO Stephen Willard resigns effective Oct 7, 2024; Chairman Jonathan Javitt appointed interim CEO.
Stockholders approved reverse stock split authorization (1:2 to 1:5) at board's discretion within one year.
Stockholders approved issuance of shares upon redemption of convertible note and warrants to institutional investors.
Company signed LOI to acquire an interventional psychiatry clinic; targeting $25M+ initial HOPE Therapeutics business and $100M+ revenue by next year.

item 5.02 item 5.07 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Jonathan Javitt

Interim Chief Executive Officer

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2024-10-07
Filed: October 11, 2024, 7:59 PM ET

Jonathan Javitt, Chairman of the Board of Directors of the Company, was appointed as Interim Chief Executive Officer concurrent with Mr. Willard’s resignation.

Departed

Stephen Willard

Chief Executive Officer

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2024-10-07
Successor: Jonathan Javitt
Filed: October 11, 2024, 7:59 PM ET

On October 7, 2024, Stephen Willard, the Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”) provided notice to the Board that he was resigning from the Company, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Javitt was appointed as Interim Chief Executive Officer at NRX Pharmaceuticals, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

Jonathan Javitt, Chairman of the Board of Directors of the Company, was appointed as Interim Chief Executive Officer concurrent with Mr. Willard’s resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Willard resigned as Chief Executive Officer at NRX Pharmaceuticals, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On October 7, 2024, Stephen Willard, the Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”) provided notice to the Board that he was resigning from the Company, effective immediately

View on SEC.gov

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-031133

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.